Elevated serum concentrations of soluble CD14 in HIV- and HIV+ patients with tuberculosis in Africa: Prolonged elevation during anti-tuberculosis treatment

Clinical and Experimental Immunology

Volumn 120, Issue 3, 2000, Pages 483-487

  Lawn, S D ^a,c,d,e   Labeta, M O ^b   Arias, M ^b   Acheampong, J W ^c   Griffin, G E ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

CD14; HIV; Immune activation; Macrophage; Tuberculosis

Indexed keywords

CD14 ANTIGEN; TUBERCULOSTATIC AGENT;

ADULT; AFRICA; ANTIGEN ANTIBODY COMPLEX; ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUBERCULOSIS;

ADULT; ANTIGENS, CD14; FEMALE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; MACROPHAGE ACTIVATION; MALE; RECEPTORS, INTERLEUKIN-2; TUBERCULOSIS;

EID: 0034121083     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01246.x     Document Type: Article

References (30)

1. 1 Ziegler-Heitbrock HWL, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. Immunol Today 1993; 14:121-5.
2. 2 Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14 serves as the cellular receptor for complexes of lipopolysaccharide with lipopolysaccharide binding protein. Science 1990; 249:1431-3.
3. 3 Dentener MA, Bazil V, Von Asmuth EJU, Ceska M, Buurman WA. Involvement of CD14 in lipopolysaccharide-induced tumour necrosis factor-α, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J Immunol 1993; 150:2885-91.
4. 4 Pugin J, Heumann ID, Tomasz A et al. CD14 is a pattern recognition receptor. Immunity 1994; 1:509-16.
5. 5 Frey EA, Miller DS, Jahr TG, Sundan A, Bazil V, Espevik T, Finlay BB, Wright SD. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 1992; 176:1665-71.
6. 6 Labeta MO, Durieux JJ, Fernandez N, Herrman R, Ferrara P. Release from a human monocyte-like cell line of two different soluble forms of the lipopolysaccharide receptor, CD14. Eur J Immunol 1993; 23:2144-51.
7. 7 Durieux JJ, Vita N, Popescu O et al. The two soluble forms of the lipopolysaccharide receptor, CD14: characterization and release by normal human monocytes. Eur J Immunol 1994; 24:2006-12.
8. 8 Vita N, Lefort S, Sozzani P, Reeb R, Richards S, Borysiewicz LK, Ferrara P, Labeta M. Detection and biochemical characteristics of the receptor for soluble complexes of soluble CD14 and bacterial polysaccharide. J Immunol 1997; 158:3457-62.
9. 9 Yu W, Soprana E, Cosetino G, Volta M, Lichenstein HS, Viale G, Vercelli D. Soluble CD14 confers responsiveness to both lipoarabinomannan and lipopolysaccharide in a novel HL-60 cell bioassay. J Immunol 1998; 161:4244-51.
10. 10 Zhang Y, Doerfler M, Lee TC, Guillemin B, Rom WN. Mechanisms of stimulation of IL-1 beta and TNF-alpha by M. tuberculosis components. J Clin Invest 1993; 91:2076-83.
11. 11 Hoheisel G, Zheng L, Teschler H, Striz I, Costabel U. Increased soluble CD14 levels in BAL fluid in pulmonary tuberculosis. Chest 1995; 108:1614-6.
12. 12 Juffermans NP, Verbon A, van Deventer SJH, Buurman WA, van Deutkom H, Speelman P, van der Poll T. Serum concentrations of lipopolysaccharide activity-modulating proteins during tuberculosis. J Infect Dis 1998; 178:1839-42.
13. 13 Wiersma SR, Ortega J, Sobel E, Weinberg KI. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med 1991; 324:800-8.
14. 14 Pforte A, Schiessler A, Gais P, Beer B, Strobel M, Schutt C, Ziegler-Heitbrock HWL. Increased expression of the monocyte differentiation antigen CD14 in extrinsic allergic alveolitis. Monaldi Arch Chest Dis 1993; 48:607-12.
15. 15 Pforte A, Schiessler A, Gais P, Beer B, Ehlers M, Schutt C, Ziegler-Heitbrock HWL. Expression of CD14 correlates with lung function impairment in pulmonary sarcoidosis. Chest 1994; 105:349-54.
16. 16 Kruger C, Schutt C, Obertacke U et al. Serum CD14 levels in polytraumatised and severely burned patients. Clin Exp Immunol 1991; 85:297-301.
17. 17 Landmann R, Reber M, Sansano S, Zimmerli W. Function of soluble CD14 in serum of patients with septic shock. J Infect Dis 1996; 173:661-8.
18. 18 Lien E, Aukrust P, Sundan A, Muller F, Froland SS, Espevik T. Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 infection: correlation to disease progression and clinical events. Blood 1998; 92:2084-92.
19. 19 Lawn SD, Shattock RJ, Acheampong JW, Lal RB, Folks TM, Griffin GE, Butera ST. Sustained plasma TNF-α and HIV-1 load despite resolution of other immune activation parameters during treatment for tuberculosis in Africans. AIDS 1999; 13:2231-7.
20. 20 Lawn SD, Roberts BD, Griffin GE, Folks TM, Butera ST. Cellular compartments of HIV-1 replication: determination by virion-associated host proteins and the impact of opportunistic infection in vivo. J Virol 2000; 74:139-45.
21. 21 Wallis RS, Nsubuga P, Whalen C et al. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis 1996; 174:727-33.
22. 22 Sada E, Aguilar D, Torres M, Herrera T. Detection of lipoarabinomannan as a diagnostic test for tuberculosis. J Clin Microbiol 1992; 30:2415-8.
23. 23 Gilks CF, Brindle RJ, Otieno LS et al. Extrapulmonary and disseminated tuberculosis in HIV-1 seropositive patients presenting to the acute medical services in Nairobi. AIDS 1990; 4:981-5.
24. 24 Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science 1997; 276:1857-61.
25. 25 Goletti D, Weissman D, Jackson RW et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol 1996; 157:1271-8.
26. 26 Vanham G, Edmonds K, Qing L et al. Generalized immune activation in pulmonary tuberculosis: coactivalion with HIV infection. Clin Exp Immunol 1996; 103:30-34.
27. 27 Wallis RS, Vjecha M, Amir-Tahmassch M et al. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated β2-microglobulin in HIV-1-associated tuberculosis. J Infect Dis 1993; 167:43-48.
28. 28 Bekker LG, Maartens G, Steyn L, Kaplan G. Selective increase in plasma tumor necrosis factor alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J Infect Dis 1998; 178:580-4.
29. 29 Toman K. Tuberculosis: case-finding and chemotherapy. Geneva: WHO, 1979:91.
30. 30 Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL. Soluble interleukin-2-receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135:3172-7.